Please enable Javascript to use all features and improve your user experience.
EHC 2023
Programme
People
Search
DE
All people
Andreas Argyriou
Sort by Type
Date
Speaker
ePoster
P009
OnabotulinumtoxinA add-on to monoclonal anti-CGRP antibodies in treatment-refractory chronic migraine
ePoster
P010
Predictors of response to fremanezumab in migraine patients with at least three previous preventive failures: post-hoc analysis of a prospective, multicenter, real-world Greek registry
ePoster
P011
Efficacy and safety of fremanezumab for migraine prophylaxis in patients with at least three previous preventive failures: prospective, multicenter, real-world data from a Greek registry
ePoster
P012
Effects of fremanezumab on psychiatric comorbidities in difficult-to-treat patients with chronic migraine: post-hoc analysis of a prospective, multicenter, real-world Greek registry
Further involvements
ePoster
P009
OnabotulinumtoxinA add-on to monoclonal anti-CGRP antibodies in treatment-refractory chronic migraine
ePoster
P010
Predictors of response to fremanezumab in migraine patients with at least three previous preventive failures: post-hoc analysis of a prospective, multicenter, real-world Greek registry
ePoster
P011
Efficacy and safety of fremanezumab for migraine prophylaxis in patients with at least three previous preventive failures: prospective, multicenter, real-world data from a Greek registry
ePoster
P012
Effects of fremanezumab on psychiatric comorbidities in difficult-to-treat patients with chronic migraine: post-hoc analysis of a prospective, multicenter, real-world Greek registry
ePoster
P197
The significance of the circadian time of administration on the effectiveness and tolerability of OnabotulinumtoxinA for chronic migraine prophylaxis
© Conventus Congressmanagement & Marketing GmbH
Imprint
Privacy